All In Biotech

Drug Trial Radar · NCT05417594

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

695

Planned (sponsor's estimate)

Start

Jun 24, 2022

Primary completion

Feb 7, 2028

Study completion Feb 7, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.

Conditions

  • Advanced Solid Malignancies

Interventions

  • AZD9574Drug

    Participants will receive AZD9574 orally.

  • Temozolomide (TMZ)Drug

    Participants will receive temozolomide orally.

  • [11C]AZ1419 3391Drug

    Participants will receive \[11C\]AZ1419 3391 intravenously.

  • Trastuzumab Deruxtecan (T-DXd)Drug

    Participants will receive T-DXd intravenously.

  • Datopotamab Deruxtecan (Dato-DXd)Drug

    Participants will receive Dato-DXd intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs)Time frame: From first dose to post-treatment follow-up (approximately three years)
  2. Changes from baseline in laboratory findings, electrocardiograms (ECGs), and vital signsTime frame: From last assessment prior to first dose to post-treatment follow up visit (approximately three years)
  3. Change from baseline Eastern Cooperative Oncology Group performance status (ECOG PS)Time frame: From last assessment prior to first dose to post-treatment follow up visit (approximately three years)
  4. Incidence of Dose Limiting Toxicities (DLTs)Time frame: Cycle 0 and Cycle 1 (Day 1 to Day 35)

Locations

32 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California · Withdrawn

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Portland, Oregon · Withdrawn

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

  • Research Site

    Richmond, Virginia · Withdrawn

  • Research Site

    Darlinghurst, Australia · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Randwick, Australia · Recruiting

  • Research Site

    Bayern, Germany · Withdrawn

  • Research Site

    Berlin, Germany · Withdrawn

  • Research Site

    Heidelberg, Germany · Withdrawn

  • Research Site

    Mainz, Germany · Withdrawn

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    A Coruña, Spain · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Málaga, Spain · Recruiting

  • Research Site

    Pozuelo de Alarcón, Spain · Recruiting

  • Research Site

    Sant Cugat del Vallès, Spain · Recruiting

  • Research Site

    Seville, Spain · Recruiting

  • Research Site

    Lund, Sweden · Recruiting

  • Research Site

    Stockholm, Sweden · Recruiting

  • Research Site

    Glasgow, Scotland, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Recruiting

  • Research Site

    Newcastle upon Tyne, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.